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ABSTRACT
Medication errors are common within the United States health system. Preventable medication
errors are often the result of ineffective processes that contribute to the occurrence of adverse drug
events. Care transitions, movement between settings or levels of care, present a particularly vulnerable
time for patients. Errors are frequently introduced into a patient's medication regimen during transitions
of care, including the inappropriate discontinuation or duplication of medications. Inappropriate
discontinuation (non-persistence) of evidence based therapies for chronic diseases places patients at an
increased risk for adverse health outcomes. Previous investigations have indicated that care transitions
due to hospitalization have been associated with increased rates of non-persistence, and that nonpersistent patients were at an increased risk for poor health outcomes.
We conducted a matched retrospective cohort study of patients enrolled with the commercial
health insurer Blue Cross Blue Shield of Rhode Island. Patients included in the study were adults at
least 18 years of age with diagnosed diabetes confirmed by outpatient medication use and a diagnosis
code. We evaluated the disruptive impact of hospitalization on the medication regimen by comparing
the odds of persistence with evidence based therapies between hospitalized and non-hospitalized
patients. Persistence was assessed with two medication classes: angiotensin converting enzyme (ACE)
inhibitors/angiotensin II receptor blockers (ARBs) and lipid lowering drugs (LLD). We classified
patients with an eligible hospitalization as exposed, and matched unexposed non-hospitalized patients to
the exposed cohort on the variables age, gender, Charlson comorbidity score and enrollment period. The
primary outcomes of persistence and treatment duplication were assessed during the 60 day period
following the hospitalized patient's discharge date. Differences in baseline characteristics and the
bivariate odds of persistence were assessed between groups for the primary risk factor hospitalization as
well as patient demographic and health related variables. We constructed multivariable logistic
regression models to measure the effect of hospitalization on persistence with medications from each
class while controlling for potential confounders and assessing for interaction terms.
A total of 201 exposed and 199 unexposed ACE inhibitor/ARB users and 202 exposed and 199
unexposed LLD users were evaluated for persistence. After adjusting for potential confounders and an
interaction term between hospitalization and cardiovascular disease, hospitalization was found to be a

significant risk factor for non-persistence in patients using ACE inhibitors/ARBs [(Beta coefficient0.931 [P = 0.0283]). Patients that were hospitalized and had cardiovascular disease had an increased
odds of persistence relative to patients that were not hospitalized and had cardiovascular disease (Odds
Ratio (OR): 2.052 [95% CI 0.384-10.972)]. Patients that were hospitalized and did not have
cardiovascular disease were significantly less likely to persist compared with patients that were not
hospitalized and did not have cardiovascular disease (OR: 0.394 [95% CI 0.171-0.906]). The odds of
persistence with LLD therapy did not differ between hospitalized patients and non-hospitalized patients
(OR: 0.961 [95% CI 0.469-1.972]). The duration of prescription supply for study medication was found
to be a confounder of the exposure and outcome relationship for both medication classes. Therapeutic
duplication occurred infrequently with both medication classes regardless of exposure status and the
low frequencies of duplication observed precluded logistic regression analysis.
Our results implicate hospitalization as a risk factor for non-persistence with medications
treating chronic diseases in commercially insured patients with diabetes. Interventions such as
medication reconciliation that strive to improve communication during transitions of care and prevent
the introduction of errors into the medication regimen should continue to be implemented and
evaluated.
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CHAPTER 1

INTRODUCTION

The conclusions heralded by The Quality of Health Care in America Committee of the Institute
of Medicine in their first report "To Err is Human: Building a Safer Health System" called for a
system-wide quest for improvement in the quality of healthcare in the United States.1 In the report, the
committee discerned that the majority of medical errors occur as a result of ineffective systems,
processes, and conditions that lead individuals to make mistakes or fail to prevent them. In 2006, a
successive report "Preventing Medication Errors" evaluated the safe, effective, and appropriate use of
medications throughout a multitude of health care settings.2 The committee estimates that on average a
hospitalized patient is subject to at least one medication error per day, and that at least a quarter of all
medication-related injuries are preventable. The financial burden of preventable adverse drug events
(ADEs) on the United States health care system is substantial. A conservative estimate of $3.5 billion
(2006 dollars) is spent annually due to in-hospital preventable ADEs.2 A care transition is the process of
shifting responsibility associated with a patient's movement between settings or level of care.3
Approximately half of all hospital related medication errors may be attributed to inefficient
communications at transitions of care.4,5
Transitions of care jeopardize the continued accuracy of a patient's medication regimen.6-10
Hospitalization places patients at risk for unintentional discontinuation of evidence based therapies for
treatment or prevention of chronic diseases.6,8 Patients undergoing an additional transition to the
intensive care unit (ICU) are at a greater risk for discontinuity in chronic medication use.6-7 The
occurrence of unintended medication discrepancies at the time of hospital admission has been estimated
to occur in greater than half of patients.9,10 A prospective study by Cornish and colleagues assessed the
accuracy of medication histories for all patients documented to be using at least 4 medications that were
admitted from the community to a large teaching hospital in Toronto, Canada.9 The original medication
history was obtained in the emergency department by either a nurse, physician, or medical
resident/student. After admission, a pharmacist, pharmacy student or medical student obtained a
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thorough medication history which was then compared with the original history. Discrepancies were
reviewed with the admitting medical team to appropriately classify intentional and unintentional
changes. Of 150 patients included in the study, 81 patients were found to have at least one discrepancy
(53.6%; 95% CI 45.7%-61.6%). A total of 140 discrepancies were identified, yielding a rate of 0.93
discrepancies per patient. Of the 140 discrepancies, 8 (5.7%) were classified as severe. A similar study
by Gleason et al compared pharmacist obtained medication histories after admission to histories
obtained by nursing and physician staff prior to admission.10 The proportion of patients with at least one
medication discrepancy was greater in this study (69% ; 1.2 discrepancies/patient [SD: 1.5]), but
discrepancies were not confirmed to be unintentional as in the study by Cornish et al.9,10
Inappropriate alteration of the medication regimen upon admission and discharge from the
hospital is associated with adverse drug events and poor health outcomes.7,8 Boockvar et al examined
the impact of care transitions on medication use in patients admitted to 2 academic hospitals from 4
different nursing homes.8 Nursing home and hospital medical records were compared for 87 patients
(122 admissions) and reviewed by 2 physicians to identify ADEs attributable to medication changes
during transitions of care. A mean of 3.1 medications were altered upon transition from the nursing
home to the hospital, which was greater than the 1.4 that were altered upon discharge back to the
nursing home (P<0.001). Of 71 bidirectional transfers reviewed, ADEs attributable to medication
changes occurred during 14 (20%) of these transfers and 7 (50%) of these medication changes were
therapy discontinuations. These results suggest that patients are at risk of adverse health outcomes due
to inappropriate medication discontinuity following transitions of care between institutions.
Patients admitted to a hospital have been demonstrated to incur higher rates of unintended
discontinuations of medications treating chronic diseases as compared to non-hospitalized patients.6
One population based cohort study evaluated the risk of unintentional discontinuation in patients
undergoing 1 or more transitions of care. Patients were required to be continuous users for at least 1
year of at least 1 medication from 5 medication classes: statins, antiplatelets/anticoagulants,
levothyroxine, respiratory inhalers, and gastric acid suppressants. Compared with non-hospitalized
patients the odds of unintentional discontinuation were increased in hospitalized patients without an
ICU stay [(statins: OR 1.33; 95% CI 1.29-1.37), (antiplatelets/anticoagulants: OR 1.86; 95% CI 1.77-
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1.97), (levothyroxine: OR 1.18; 95% CI 1.14-1.23), (respiratory inhalers: OR 1.50; 95% CI 1.15-1.97),
and (gastric acid suppressants: OR 1.50; 95% CI 1.43-1.56)] and increased further in hospitalized
patients with an ICU stay [(statins: OR 1.48; 95% CI 1.39-1.57), (antiplatelets/anticoagulants: OR 2.31;
95% CI 2.07-2.57), (levothyroxine: OR 1.51; 95% CI 1.38-1.66), (respiratory inhalers: OR 1.84; 95%
CI 1.10-3.08), and (gastric acid suppressants: OR 1.87; 95% CI 1.71-2.05)]. These results demonstrate
the disruptive impact one or more hospitalization related transitions of care may have on appropriate
medication use in elderly patients.6
National and International Focus on Medication Management During Care Transitions
The Joint Commission is an independent non-profit organization responsible for the
accreditation and certification of health care organizations and programs in the United States. The Joint
Commission's 2014 Hospital National Patient Safety Goal 03.06.01 specifies the maintenance and
communication of accurate patient medication information.11 Performance elements for this goal
emphasize the performance of comprehensive medication reconciliation procedures.11 The Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 included legislation that provided
reimbursement under the newly created Medicare Part D for medication therapy management
programs.12 A year later eleven national pharmacy professional organizations collaborated to provide a
widely applicable and reimbursable definition of medication therapy management.13
Medication reconciliation, a primary component of medication therapy management, was later
defined by an expert panel representing the American Pharmacists Association and the American
Society of Health System Pharmacists in 2007.14 An abbreviated version of the joint definition states
that medication reconciliation is the comprehensive evaluation of a patient's medication regimen during
any change in therapy in an effort to avoid errors or interactions, as well as to observe compliance and
adherence patterns. A comparison of existing and previous regimens should occur at every transition in
care during which the regimen is modified.14 The use of pharmacists or other qualified healthcare
professionals for medication reconciliation purposes during care transitions presents the potential for
limiting medication errors and improving health outcomes.15-26
The World Health Organization (WHO) introduced the High 5's project in 2006 as an
international initiative responsible for the implementation and evaluation of five standard operating
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procedures (SOP) for the improvement of five areas of patient safety.27 An SOP for medication
reconciliation entitled, " Medication Accuracy at Transitions in Care: SOP for Medication
Reconciliation" was developed in Canada and is in the process of being implemented and evaluated in
the Netherlands. Results reported in 2013 from the use of the SOP in 12 Dutch hospitals indicated a
reduction in the proportion of elderly patients with at least one unintentional medication discrepancy
upon admission from the emergency department.28 An intervention consisting of a medication history
obtained by a pharmacy technician was associated with a reduced odds of at least one unintentional
medication discrepancy [OR 0.29; 95% CI = 0.23-0.37] compared with usual care involving a nurse or
physician obtained medication history.28 Complete results and disclosure of the SOP is planned for
2015.29
Adherence and Persistence
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Medication Compliance and Persistence Work Group defines compliance (synonym: adherence) as "the
extent to which a patient acts in accordance with the prescribed interval and dose of a dosing
regimen".30 The ISPOR Work Group defines persistence as "the duration of time from initiation to
discontinuation of therapy". Persistence analyses must also include a pre-specified limit on the number
of days allowed between refills before a patient is identified as non-persistent.30 Poor adherence to
evidence based therapy has been frequently documented in outpatient populations.31-32 Non-persistence
and sub-optimal adherence prevents the full therapeutic benefit of a drug from being realized and is a
cause of preventable adverse health outcomes including mortality.33-36 Inappropriate medication taking
behavior increases resource utilization and the risk of mortality, leading to parallel increases in
economic costs and burdens on the health care system.2, 37-38
Lipid Lowering and Antihypertensive Therapy in Patients with Diabetes
The prevalence of diagnosed diabetes mellitus has increased steadily from an age adjusted
2.8% of the United States non-institutionalized population in 1980 to 6.4% in 2011.39 Persons with
diabetes mellitus require appropriate lifestyle and medication interventions to mitigate an elevated risk
of microvascular and macrovascular complications.40 Management of dyslipidemia using statin therapy
is recommended regardless of baseline lipid levels in patients with cardiovascular disease (CVD) or in
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those older than 40 years of age without CVD but that have at least one other CVD risk factor
identified.41 Statin therapy is also recommended in patients that are younger than 40 years of age having
multiple CVD risk factors or having a low density lipoprotein (LDL) cholesterol level of greater than
100 mg/dL.41 The risk of major vascular events and all cause mortality is reduced in patients with
diabetes using statin therapy for either primary or secondary prevention.42-44 In a meta analysis of over
18,000 patients with diabetes from 14 randomized controlled trials, statin therapy was associated with a
9% reduction in all-cause mortality and a 13% proportional reduction in vascular mortality for each
millimole per liter reduction in low density lipoprotein (LDL) cholesterol.43
Inhibitors of the renin-angiotensin system (RAS) are preferred as initial therapy for
hypertension in patients with diabetes due to associated reductions in the occurrence of microvascular
and macrovascular outcomes.40 The HOPE study evaluated the use of the ACE inhibitor ramipril
compared with placebo in 3,577 patients with diabetes.45 Patients were at least 55 years of age and had a
history of a prior cardiovascular event or at least one current cardiovascular disease risk factor. The
study was stopped before completion due to pronounced beneficial effects in patients receiving
ramipril. The combined primary outcome of myocardial infarction, stroke, or cardiovascular death was
reduced by 25% (95% CI: 12-36; P=0.0004), total mortality was reduced by 24% (95% CI: 8-37%) and
nephropathy was also reduced by 24% (95% CI: 3-40%; P=0.027).45 The 2014 Standards of Diabetes
Care recommend that patients with diabetes and a confirmed blood pressure greater than 140/80 mmHg
have prompt initiation and titration of pharmacological antihypertensive therapy. Pharmacological
therapy should include either an angiotensin-enzyme (ACE) inhibitor or an angiotensin receptor blocker
(ARB), substituting one class for the other if the first is not tolerated.40
Purpose and Hypothesis
The purpose of this study was to investigate the potential disruptive impact that hospitalization
may have on medication persistence with critical medication classes used in patients that have diabetes.
In patients with confirmed use of at least one of two classes of these evidence based medications, we
determined if the prescriptions were renewed in the 60 day period after discharge. Furthermore, we
compared the medication discontinuation rate of hospitalized patients to that of matched patients that
were not hospitalized. Additionally, we measured the rate of treatment duplication (multiple
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prescriptions from the same medication class) between hospitalized and non-hospitalized patients. The
effect of time to follow up with a primary care physician on persistence was also examined among
patients that were hospitalized.
We expected hospitalization to affect a patient's medication regimen and medication taking
behavior due to multiple system related factors. Upon arrival to the hospital, a medication history is
obtained by emergency room staff. The completeness and accuracy of medication histories obtained
prior to or during the admission process are likely to vary depending upon systemic factors including
hospital policies, procedures and staffing models. During the course of a hospitalization, medications
treating chronic diseases are often suspended and new medications are added in the course of managing
the acute inpatient episode. Substitution of hospital formulary medications will also occur for nonformulary drugs that a patient uses at home. As a patient is prepared for discharge, new medications
added during the hospitalization may be continued and chronic medications may be resumed depending
upon the patient's condition. Hospital formulary drugs should be changed back to the patient's original
medication used prior to admission. Effective communication between hospital practitioners, the patient
and/or caregiver, and outpatient practitioners is necessary to reduce the risk for introduction of errors
into the medication regimen.
A patient's medication taking behavior, encompassing adherence and persistence with
prescribed therapies, is expected to be impacted by a hospitalization. The Necessity Concerns
Framework proposes that patient perceptions of their own need for treatment and the potential for
adverse consequences related to treatment are the main categories of beliefs that influence patient
adherence.46 Application of this conceptual framework in research studies has shown that adherence
increases with parallel increases in perceived necessity of therapy and decreases in concerns regarding
the medication.46 The experience of acute hospitalization may increase a patient's perceived disease
severity, therefore increasing the likelihood of adherence after discharge. Alternatively, it is possible
that a patient attributes a hospitalization to a lack of effect or adverse consequence of their medication
leading to decreased adherence after discharge.
Evidence based medications for which persistence and treatment duplication were assessed in
this study consisted of two classes, LLDs and ACE inhibitors/ARBs. ACE inhibitors and ARBs are
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used interchangeably in therapy and were regarded as a single class of medications for this study. We
hypothesized that hospital admission would increase the likelihood that disruption of a patient's
medication regimen would occur, thus causing unintentional discontinuation of evidence based
therapies as well as duplications of drug therapy in error. We expected disruption to occur because of
the many systematic modifications made to the medication regimen during hospitalization, and due to
absent or sub-optimal hospital based medication reconciliation practices. We expected that along with
hospitalization, a longer time to follow up with a primary care provider would be associated with a
decreased likelihood of persistence due to a longer time until potential resolution of errors introduced
into the medication regimen.
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CHAPTER 2

METHODOLOGY

The study was conducted as a matched retrospective cohort study of patients with diabetes
enrolled with a commercial insurer. The data for this research were provided by Blue Cross Blue Shield
of Rhode Island and contained information on enrollment and demographics, as well as pharmacy and
medical claims. Patients were at least 18 years of age as of July 1, 2008 and continuously enrolled for at
least 12 months between the period of July 1, 2008 to December 31, 2009. All patients were confirmed
to have a diagnosis code for diabetes. International classification of diseases ninth edition (ICD-9)
codes from the 2009 Healthcare Effectiveness Data and Information Set (HEDIS)47 were used to
identify the presence of any code indicative of diabetes or a diabetes related complication (Appendix A)
throughout each patient's period of continuous enrollment. In addition, all patients were confirmed to
have used a medication for the treatment of diabetes, defined as the presence of a claim for any oral or
injectable hypoglycemic agent during each patient's continuous enrollment period. Patients were
identified using unique identification (ID) numbers in the data file; IDs without associated values for
date of birth, gender, and eligibility were removed from the study population.
Defining Exposure
The primary outcome of interest in this study was the odds of persistence with chronic
medications between hospitalized and non-hospitalized patients. The exposed group in this study
consisted of patients hospitalized for at least one night (claims from two consecutive days) and for no
greater than 30 days. Patients with multiple hospitalizations during the study period were excluded from
the patient population. Current Procedural Terminology (CPT) codes from the 2009 HEDIS (Appendix
B)47 were used to identify acute and non-acute inpatient episodes of care representative of an eligible
hospitalization. Coding for emergency department visits was not included in the definition of an eligible
hospitalization. Patients with an eligible hospitalization stay were required to have 180 days of
continuous enrollment prior to the date of admission and 60 days after the date of hospital discharge.
Medication use was evaluated prior to hospital admission with two medication classes (Appendix C),
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angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) and lipid
lowering drugs (LLD). Inclusion into the final cohort of exposed patients required at least two
prescription claims for one or more medications within one of these classes during the 180 days prior to
hospitalization. Separate analyses were conducted for each medication class, allowing for patients to be
included in each analysis group if medications from both classes were used during the baseline period.
Unexposed Matching
Patients without a hospital stay during the study period were unexposed and a source of
potential matches for eligible exposed patients. Hospitalized patients were initially linked with all
potential matches that consisted of non-hospitalized patients of the same age and gender. Of these
potential matches, patients with an enrollment period that encompassed the entire 180 day baseline and
60 day post hospitalization period of the linked exposed patient were retained. Matched patients were
assigned an index date identical to the relevant hospitalized patient, with entirely coincident baseline
and follow up periods. At least two prescription claims for the same study medication class used by the
hospitalized patient were confirmed for potential matches during the 180 day baseline period. The final
matching criterion was a comorbidity score calculated using weights as described by Charlson et al and
updated ICD-9 codes identified by Quan et al.48,49 A comorbidity score was calculated for all patients
and the distribution of scores was then divided into four groups. Since all patients had previously been
confirmed to have a diagnosis of diabetes, the comorbidity score was calculated without diabetes
diagnoses. Diabetes related complications were still included in the score calculation. The majority of
patients had a minimal comorbid disease burden and the distribution of the comorbidity score was
highly skewed (Appendix D). Due to the skewed distribution, the four groups were created as follows:
no comorbid disease (score of 0), one comorbid disease (score of 1), patients with two comorbid
diseases (score of 2), and three or more comorbid diseases (score of >3). Potential matches with the
same comorbidity grouping as the hospitalized patient met all criteria and were eligible to be matched.
Matches were assigned to hospitalized patients on a one to one basis without replacement. If a
hospitalized patient had multiple eligible matches, a random number was assigned to all potential
matches and a final match was assigned at random.
Defining Persistence
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Persistence was previously defined by the ISPOR Workgroup as "the duration of time from
initiation to discontinuation of therapy".30 In our study all patients were required to have at least two
claims during the baseline period prior to the index hospitalization, and a third claim during the follow
up period was indicative of continued use of the medication (persistence). Persistence was evaluated as
a dichotomous variable during the 60 day period following the discharge date of the hospitalized and
matched patients. Patients without a prescription claim for any medication during this period were
excluded from the analysis. Persistence was confirmed if the patient filled a prescription during the 60
day follow up period for any medication within the study drug class of interest. Patients without a claim
for such a prescription were classified as non-persistent.
Defining Therapeutic Duplication
Therapeutic duplication was evaluated as a dichotomous variable during the 60 day period
following the discharge date of the hospitalized and matched patients. Patients without a prescription
claim during the follow up period were excluded from this analysis. Therapy was considered duplicated
if claims were identified for greater than one generic medication name within a study drug class (ACE
inhibitors/ARBs and LLD) during the post discharge period. Changes in dosing were not captured as
therapeutic duplications. To reduce the potential for misclassifying patients using ACE inhibitors/ARBs
who were intentionally prescribed multiple medications within the same class, patients confirmed to
have been on multiple medications within the same class during the baseline period were excluded. To
reduce the potential for misclassifying patients intentionally prescribed multiple LLD, therapeutic
duplication was evaluated only for statins. Statins are the most commonly used class of LLD and there
is no clinical situation in which duplicating statin therapy is considered appropriate.41
Potential Confounding Variables
Age: Parametric assessment of the relationship between the continuous variable age and the
dichotomous variable persistence for patients using ACE inhibitors/ARBs depicted a non-linear
relationship. Age was coded categorically into three groups for the ACE inhibitor/ARB analysis. Age
was determined to have a linear relationship with persistence for patients using lipid lowering drugs,
and was coded as a continuous variable.
Gender: Analyzed as a dichotomous variable.
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Comorbidity Score Category: The comorbidity score was constructed based upon ICD-9 coding from
the 180 day baseline period. This variable was grouped into four categories due to its skewed
distribution. The comorbidity score grouping was used as a criteria for matching non-hospitalized
patients to hospitalized patients.
Days' Supply: Patients in this study that received prescriptions containing a supply of medication for a
period greater than the duration of follow up (60 days) were at risk for misclassification of persistence.
Hospitalized patients may have additional medication remaining from a prescription filled prior to
hospitalization, and non-hospitalized patients may have filled a prescription for a duration greater than
60 days that is not due for a refill during the follow up period. Duration of prescription supply, in days,
was evaluated during the 180 day baseline period and included in the analysis as a dichotomous
variable to control for the potential of misclassification.
Individual Comorbid Diseases: The presence of comorbid cardiovascular, respiratory, and mental health
disease was identified during the 180 day baseline period using ICD-9 codes from the HEDIS 2009
(Appendix D). The cardiovascular disease variable comprised codes for congestive heart failure,
coronary artery disease, myocardial infarction, and other forms of ischemic and non-ischemic
cardiovascular disease. Respiratory disease comprised codes for bronchitis, emphysema, and asthma.
Mental health disorders included codes for schizophrenia, bipolar disorder, major depression, paranoia,
psychosis, anxiety, autism, panic disorder, personality disorders, acute stress disorders, impulse control
disorders, anger/aggression disorders, attention deficit disorder, and attention hyperactivity deficit
disorder.
Diabetes Medication Regimen: The outpatient diabetes medication regimen was evaluated during the
180 day baseline period and considered a surrogate for severity of disease. This variable was classified
categorically into four groups: no outpatient diabetes medication use, monotherapy (no insulin use),
polytherapy (no insulin use), and any insulin use.
Medication regimen complexity: Regimen complexity was calculated as the number of unique chemical
entities dispensed in the 180 day timeframe preceding the index hospitalization. This variable was
determined to have a non-linear relationship with persistence for both medication classes and was coded
categorically into four groups based upon quartiles of distribution.
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Time Until Primary Care Physician Visit: The time until follow up with a primary care physician was
assessed only for hospitalized patients during the 60 day post discharge period and presented as
frequencies and percentages.
Statistical Analysis:
Statistical Analysis Software Version 9.3 was used to analyze the data. Patient characteristics
of the final matched cohort were stratified by exposure (hospitalization) status and frequency
distributions were presented separately for each study medication class in Table 1 (ACE
inhibitors/ARBs) and Table 1a (LLD). The Pearson Chi square test was used to assess differences
between groups. Continuous variables were compared using t-tests for independent samples or
Satterthwaites approximate t-test for variables with unequal variance. The bivariate relationships
between hospitalization and persistence, and between other potential confounders and persistence, are
presented in Table 2 (ACE inhibitors/ARBs) and table 2a (LLD). Frequencies and percentages of
patients persisting were presented for each characteristic as well as the bivariate odds of persistence.
Results with a P-value < 0.05 were statistically significant.
Risk factor logistic regression modeling was employed to construct two multivariable models,
one each for the matched cohort of patients using ACE inhibitors/ARBs (Table 3a) and the matched
cohort of patients using lipid lowering drugs (Table 3b). Hospitalization was the risk factor of interest,
with all other independent variables considered potential confounders of the relationship with the
dependent variable of persistence. Assessment for collinearity was conducted with all possible
confounders for each model. The presence of collinearity was determined based upon identifying a
large condition index (>20) with multiple variables associated with a proportion of variance > 0.50. To
evaluate if inclusion of interaction terms improved the model fit, the log likelihood test was used to
compare models with interaction terms to reduced models. The difference in the –2 log statistic between
the full model and the reduced model was compared to the corresponding Chi square statistic with the
degrees of freedom equal to the difference in the number of terms in the models. The full model
contained all possible two-way interactions, and a backwards elimination process was used to remove
the least significant interaction terms at each step. Only interaction terms with a p-value < 0.10 were
retained in the final model.
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A confounding assessment was performed for all variables. The hospitalization beta estimate
for the full model with all variables and retained interaction terms was used as the standard for
comparison. The effect each variable had on the hospitalization beta estimate was evaluated by
comparing the full model estimate to the estimate from a reduced model containing all items except for
the variable being assessed (Appendix E).. Variables that conferred a significant change in the beta
estimate when eliminated from the model were identified as confounders that were important for
inclusion in the final multivariable model. The final multivariable model for each drug class contained
all significant confounders, interaction terms, and other variables deemed clinically important for model
inclusion. The c statistic and the Hosmer-Lemeshow goodness of fit test assessed the calibration of the
final model (Appendix F).
Therapeutic duplication within each medication class was evaluated and presented as
frequencies and percentages. The frequencies and percentages of hospitalized patients persisting as a
function of time to follow up with a primary care provider were presented separately (Table 4 and Table
4a). Time to follow up with a primary care provider was dichotomized at the median, which was the
same for both hospitalized ACE inhibitor/ARB users and LLD users.

13

CHAPTER 3

RESULTS

A total of 8,891 patients met all inclusion criteria (Figure1) and were subsequently evaluated
for selection into the exposed cohort of hospitalized patients (Figure 2). Of these patients, 270 were
confirmed to have had an eligible hospitalization in conjunction with the use of medication from a study
drug class prior to admission (207 ACE inhibitors/ARBs and 206 LLD). A total of 7,421 patients
without a hospitalization were assessed for matching eligibility with patients in the exposed cohort. An
equal number of unique non-hospitalized patients were assigned as matches for the two cohorts of
hospitalized patients. After matching was performed, any exposed or unexposed patients without at
least one prescription claim in the follow up period were excluded prior to analysis. The final cohort of
patients using ACE inhibitors/ARBs that were evaluated for persistence consisted of 201 exposed and
199 unexposed individuals. The final cohort of patients using lipid lowering drugs that were evaluated
for persistence consisted of 202 exposed and 199 unexposed individuals.
ACE Inhibitor/ARB Baseline Characteristics
The analytic cohort of ACE inhibitor/ARB users was comprised of 400 patients (Table 1). The
exposed and unexposed patients did not differ on the matched variables of age, gender and comorbidity
index grouping. The mean (standard deviation [SD]) age of hospitalized patients and non-hospitalized
patients was 56.84 [7.82] and 56.86 [7.80], respectively. There was no statistically significant difference
in age between groups for each stratum (P > 0.947 for all 3 stratum). The majority of the cohort was
male, 66.67% of the hospitalized group of patients and 65.83% of the non-hospitalized group
(P=0.859). The prevalence of respiratory, cardiovascular and mental health disease was significantly
different between groups. Patients with respiratory disease made up 13.93% of the hospitalized group
and 7.04% of the non-hospitalized group (P=0.025). Patients with cardiovascular disease made up
24.38% of the hospitalized group and 14.57% of the non-hospitalized group (P=0.013). Patients with
mental health disorders made up 16.92% of the hospitalized group and 8.54% of the non-hospitalized
group (P=0.012). Variability existed between groups with regards to outpatient diabetes medication
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regimens used during the baseline period. Of hospitalized patients, 7.46% were using no diabetes
medication, 24.38% were using monotherapy without insulin, 39.80% were using polytherapy without
insulin, and 28.36% were using insulin alone or in combination with other medications. Of nonhospitalized patients, 5.53% were using no diabetes medication (P=0.433), 38.69% were using
monotherapy without insulin (P=0.002), 35.18% were using polytherapy without insulin (P=0.339), and
20.60% were using insulin alone or in combination with other medications (P=0.071). Hospitalized
patients utilized a significantly larger mean number of distinct medications (10.79 [4.81]) compared
with non-hospitalized patients [(8.66 [4.40]), (P<0.001)]. Finally, 19.10% of unexposed patients had a
prescription supply of greater than 60 days compared with 10.45% in the exposed group. Nonhospitalized patients were significantly more likely to have a prescription supply of greater than 60 days
(P=0.0147).
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Figure 1 Eligibility Flowchart: Application of Inclusion and Exclusion Criteria
21,153 unique patient IDs

Missing values for DOB, gender, and/or
eligibility (exclude 13)

N = 21,140

Patients not enrolled for 12 consecutive
months (exclude 1,862)

N = 19,278

Not age 18 before July 1, 2008
(exclude 172)

N = 19,106

Absence of ICD-9 code for diabetes or
diabetes related disorder (exclude 4,331)
N = 14,775

ID not present in the prescription claims data
file (exclude 3,235)

N = 11,540

No prescription claim for a diabetes medication
(exclude 2,649)

N = 8,891
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Figure 2

Exposure Classification Flowchart
8,891 patients eligible for inclusion

7,421 patients without a hospitalization
(Potential matches)

1,470 patients with >1 hospitalization

Patients without an overnight stay
(exclude 625)

N = 845

Patients not enrolled with prescription data for
180 days prior to and 60 days after
hospitalization (exclude 438)

N = 407

Patients without at least 2 claims for
medications within either study drug class
during the 180 day baseline (exclude 137)
N = 270

Patients with least two claims for ACE
inhibitors/ARBs during the baseline period
N = 207

Patients with least two claims for lipid
lowering drugs during the baseline period
N = 206

Patients without a
prescription claim post
hospitalization (exclude 6)

Patients without a
prescription claim post
hospitalization (exclude 5)

Hospitalized patients using ACE
inhibitor/ARB therapy included for analysis
N = 201

Hospitalized patients using lipid lowering
drug therapy included for analysis
N = 201
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Table 1

Baseline Characteristics of Hospitalized and
Non-hospitalized Patients Using ACE inhibitor/ARB Therapy

Characteristic

Hospitalized
(Exposed) N = 201
% (n)

Non-Hospitalized
(Unexposed) N = 199
% (n)

P Value

Days' Supply
<60 days
>60 days

% (n)
89.55 (180)
10.45 (21)

% (n)
80.90 (161)
19.10 (38)

P Value
0.0147*

Mean Age [SD]
56.84 [7.82]
56.86 [7.80]
% (n)
% (n)
53.73 (108)
53.77 (107)
23.88 (48)
24.12 (48)
22.39 (45)
22.11 (44)

P Value
0.981
P Value
0.994
0.955
0.947

Age, years
Age < 59
59 < Age <63
63 < Age
Gender
Male
Female
Comorbid Diseases
Asthma/COPD
Cardiovascular
Mental Health
Diabetes Drug
Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use
Regimen Complexity

<6 Medications
6-8 Medications
9-12 Medications
12< Medications

% (n)
66.67 (134)
33.33 (67)

% (n)
65.83 (131)
34.17 (68)

P Value
0.859

% (n)
13.93 (28)
24.38 (49)
16.92 (34)

% (n)
7.04 (14)
14.57 (29)
8.54 (17)

P Value
0.025*
0.013*
0.012*

%

(n)

%

7.46 (15)
24.38 (49)
39.80 (80)
28.36 (57)

(n)

P Value

5.53 (11)
38.69 (77)
35.18 (70)
20.60 (41)

0.433
0.002*
0.339
0.071

Mean [SD] Number
10.79 [4.81]
8.66 [4.40]
% (n)
% (n)
10.45 (21)
24.12 (48)
22.89 (46)
331.7 (66)
35.82 (72)
27.64 (55)
30.85 (62)
15.08 (30)

P Value
<0.001
P Value
<0.001*
0.022*
0.079
<0.001*

Comorbidity Indexa
% (n)
% (n)
P Value
No Comorbid
55.72 (112)
55.28 (110)
0.929
Diseases
Comorbidity Score = 1
15.92 (32)
15.58 (31)
0.925
Comorbidity Score = 2
15.42 (31)
16.08 (32)
0.857
Comorbidity Score > 3
12.94 (26)
13.07 (26)
0.969
a
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant. Pearson chi-square test was used for all categorical comparisons and
the independent t-test for continuous variables with equal variance or Satterthwaites
approximate t-test if variance was unequal
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Lipid Lowering Drug Baseline Characteristics
The analytic cohort of lipid lowering drug users was composed of 401 patients (Table 1a). The
exposed and unexposed patients did not differ on the matched variables of age, gender and comorbidity
index grouping. The mean (standard deviation [SD]) age of hospitalized patients and non-hospitalized
patients was 57.16 [7.42] and 57.23 [7.39], respectively (P=0.927). Males made up 66.83% of the
hospitalized group of patients and 68.34% of the non-hospitalized group (P=0.747). The prevalence of
respiratory and mental health disease was significantly different between groups. Patients with
respiratory disease made up 14.85% of the hospitalized group and 7.04% of the non-hospitalized group
(P=0.012). Patients with mental health disorders made up 17.33% of the hospitalized group and 8.04%
of the non-hospitalized group (P=0.005). Cardiovascular disease was unbalanced between groups but
the difference was not statistically significant. Patients with cardiovascular disease made up 26.24% of
the hospitalized group and 18.59% of the non-hospitalized group (P=0.067). Significantly more nonhospitalized patients utilized single drug outpatient diabetes regimens, whereas significantly more
hospitalized patients utilized regimens involving insulin. Of hospitalized patients, 6.44% were using no
diabetes medication, 27.23% were using monotherapy without insulin, 36.63% were using polytherapy
without insulin, and 29.70% were using insulin alone or in combination with other medications. Of nonhospitalized patients, 6.03% were using no diabetes medication (P=0.867), 38.69% were using
monotherapy without insulin (P=0.145), 35.18% were using polytherapy without insulin (P=0.991), and
18.59% were using insulin alone or in combination with other medications (P=0.009). Hospitalized
patients utilized a significantly larger mean number of distinct medications (10.79 [4.54]) compared
with non-hospitalized patients [(8.28 [3.73]), (P=0.001)]. Significant differences between groups also
existed across all four stratum of the regimen complexity variable. Finally, 15.58% of unexposed
patients had a prescription supply of greater than 60 days compared with 9.90% in the exposed group,
this difference was not statistically significant (P=0.088).
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Table 1a

Baseline Characteristics of Hospitalized and
Non-hospitalized Patients Using Lipid Lowering Drug Therapy

Characteristic

Hospitalized Patients
(Exposed)
N = 202
% (n)

Non-Hospitalized
Patients (Unexposed)
N = 199
% (n)

P Value

% (n)
90.10 (182)
9.90 (20)

% (n)
84.42 (168)
15.58 (31)

P Value
0.088

Mean Age [SD]
57.16 [7.42]
57.23 [7.39]

P Value
0.927

Gender
Male
Female

% (n)
66.83 (135)
33.17 (67)

% (n)
68.34 (136)
31.66 (63)

P Value
0.747

Comorbid Diseasesc
Asthma/COPD
CVD
Mental Health Diagnosis

% (n)
14.85 (30)
26.24 (53)
17.33 (35)

%
7.04
18.59
8.04

(n)
(14)
(37)
(16)

P Value
0.012*
0.067
0.005*

Diabetes Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use

% (n)
6.44 (13)
27.23 (55)
36.63 (74)
29.70 (60)

% (n)
6.03 (12)
38.69 (77)
36.68 (73)
18.59 (37)

P Value
0.867
0.0145*
0.991
0.009*

Mean [SD] Number
10.79 [4.54]
8.28 [3.73]
% (n)
% (n)
6.93 (14)
23.12 (46)
25.25 (51)
35.68 (71)
38.12 (77)
27.14 (54)
29.70 (60)
14.07 (28)

P Value
<0.001
P Value
<0.001*
0.023*
0.019
<0.001*

Days' Supply
<60 days
>60 days
Age, years

Regimen Complexity

<6 Medications
6-8 Medications
9-12 Medications
12< Medications

Comorbidity Indexa
% (n)
% (n)
P Value
No Comorbid Diseases
52.97 (107)
53.27 (106)
0.953
Comorbidity Score = 1
11.88 (24)
11.56 (23)
0.920
Comorbidity Score = 2
17.33 (35)
16.58 (33)
0.843
Comorbidity Score > 3
17.82 (36)
18.59 (37)
0.841
a
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant. Pearson chi-square test was used for all categorical comparisons and the
independent t-test for continuous variables with equal variance or Satterthwaites approximate ttest if variance was unequal
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Bivariate Odds of Persistence with ACE Inhibitors/ARBs
The bivariate relationship between the dependent variable, persistence with ACE
inhibitors/ARBs and all other variables are presented as odds ratios with 95% confidence intervals (OR
[95% CI]) (Table 2). Hospitalization, the risk factor of interest, was associated with a decreased
likelihood of persistence that did not attain statistical significance (0.733 [0.385 - 1.398]). Patients
receiving a prescription supply of greater than 60 days had a significantly decreased odds of persistence
with study medication than those with supplies less than 60 days (0.195 [0.098 - 0.392]). The mean
(mean [standard deviation]) age of patients that persisted (57.02 [7.81]) was greater than those that did
not (55.38 [7.63]). Increasing odds of persistence was observed within each age stratum, but none were
significant. Gender was not associated with a change in the likelihood of persistence. Patients with
comorbid respiratory disease were slightly more likely to persist (1.589 [0.469 - 5.386]), whereas
patients with a comorbid mental health diagnosis were slightly less likely to persist (0.701 [0.293 1.673]). Comorbid cardiovascular disease was not associated with a change in the likelihood of
persistence. The odds of persistence relative to patients taking no medication for their diabetes was
increased in those using single drug therapy (3.091 [0.834 - 11.454]) and in patients using any insulin
(1.600 [0.458 - 5.585]) but unchanged in those using multiple drug therapy. The mean number of
distinct medications used during the baseline period was not different between persistent (9.718
[4.759]) and non-persistent patients (9.833 [4.509]). Similarly, there were no differences in odds of
persistence between the four stratum of regimen complexity. Relative to patients with a comorbidity
score of 0, those with a comorbidity score of 1 (1.539 [0.566 - 4.187]) or 2 (1.957 [0.656 - 5.832)] had a
non-significantly increased odds of persistence. A comorbidity score of 3 or greater was not associated
with a change in the likelihood of persistence.
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Table 2

Risk of Non-persistence with ACE Inhibitor/ARB Therapy Post Hospitalization
Associated with Patient Demographic and Clinical Characteristics:
Bivariate Analyses
Characteristic
Persistent
Non-persistent
Odds Ratio
(N = 358)
( N = 42)
(95% CI)
% (n)
% (n)
90.95 (181)
10.05 (18)
Reference
Not Hospitalized
88.06 (177)
11.94 (24)
0.733 (0.385 - 1.398)
Hospitalized
Days' Supply
<60 days
>60 days
Age, years

Age < 59
59 < Age <63
63 < Age

% (n)
88.27 (316)
11.73 (42)

% (n)
59.52 (25)
40.48 (17)

Mean Age [SD]
57.022 [7.813]
55.381 [7.635]
% (n)
% (n)
57.23 (187)
66.67 (28)
24.58 (88)
19.05 (8)
23.18 (83)
14.29 (6)

Odds Ratio (95% CI)
Reference
0.195* (0.098 - 0.392)
P Value
0.197
Odds Ratio (95% CI)
Reference
1.647 (0.721 - 3.761)
2.071 (0.826 - 5.191)

Gender
Male
Female

% (n)
66.20 (237)
33.80 (121)

% (n)
66.67 (28)
3.33 (14)

Odds Ratio (95% CI)
Reference
1.02 (0.518 - 2.011)

Comorbid Diseasesa
Asthma/COPD
Cardiovascular
Mental Health

% (n)
10.89 (39)
19.55 (70)
12.29 (44)

% (n)
7.14 (3)
19.05 (8)
16.67 (7)

Odds Ratio (95% CI)
1.589 (0.469 - 5.386)
1.033 (0.458 - 2.329)
0.701 (0.293 - 1.673)

Diabetes Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use

% (n)
6.15 (22)
33.24 (119)
36.03 (129)
24.58 (88)

% (n)
9.52 (4)
16.67 (7)
50.00 (21)
23.81 (10)

Odds Ratio (95% CI)
Reference
3.091 (0.834 - 11.454)
1.117 (0.350 - 3.566)
1.600 (0.458 - 5.585)

Regimen Complexity

<6 Medications
6-8 Medications
9-12 Medications
12< Medications

Mean Number [SD]
9.718 [4.759]
9.833 [4.509)
% (n)
% (n)
17.04 (61)
19.05 (8)
28.21 (101)
26.19 (11)
32.12 (115)
28.57 (12)
22.63 (81)
26.19 (11)

P Value
0.881
Odds Ratio (95% CI)
Reference
0.830 (0.317 - 2.179)
0.796 (0.309 - 2.051)
1.036 (0.393 - 2.730)

Comorbidity Indexb
% (n)
% (n)
Odds Ratio (95% CI)
CMI Score = 0
54.75 (196)
16.67 (26)
Reference
CMI Score = 1
16.20 (58)
11.90 (5)
1.539 (0.566 - 4.187)
CMI Score = 2
16.48 (59)
9.52 (4)
1.957 (0.656 - 5.832)
CMI Score > 3
12.57 (45)
16.67 (7)
0.853 (0.348 - 2.088)
a
Reference is the absence of the comorbidity
b
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant. Pearson chi-square tests used for categorical variables and independent ttests for continuous with equal variance or Satterthwaites approximate t-test if unequal variance
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Bivariate Odds of Persistence with Lipid Lowering Drugs
The bivariate relationship between the dependent variable, persistence with lipid lowering
drugs, and all other variables are presented as odds ratios with 95% confidence intervals (Table 2a).
Hospitalization was not associated with any alteration in the likelihood of persistence (0.918 [0.491 1.719]). Patients receiving a prescription supply of greater than 60 days had a significantly decreased
odds of persistence with study medication than those with supplies less than 60 days (0.167 [0.083 0.337]). The mean (mean [standard deviation]) age of patients that persisted (57.20 [7.25]) was
equivalent to those that did not persist (57.16 [8.58]). Gender was not associated with a change in the
likelihood of persistence. Patients with comorbid respiratory disease were slightly less likely to persist
(0.754 [0.299 - 1.901]). Comorbid mental health or cardiovascular disease were not associated with a
change in the likelihood of persistence. The odds of persistence relative to patients taking no medication
for their diabetes was increased in those using single drug therapy (2.750 [0.864 - 8.756]), multiple drug
therapy (1.912 [0.635 - 5.759]) and in patients using any insulin (1.955 [0.610 - 6.258]). The mean
number of distinct medications used during the baseline period was not different between persistent
(9.49 [4.40]) and non-persistent patients (9.98 [3.80]). Compared to patients using the fewest number of
medications (less than 6) during the baseline period, those in each other stratum of regimen complexity
(6-8, 9-12, 12< medications) were more likely to persist. Relative to patients with a comorbidity score
of 0, those with a comorbidity score of 1 or 2 had a comparable likelihood of persistence. A
comorbidity score of 3 or greater was associated with an increased odds of persistence (1.891 [0.698 5.122]).
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Table 2a
Risk of Non-persistence with Lipid Lowering Drug Therapy Post
Hospitalization Associated with Patient Demographic and Clinical Characteristics:
Bivariate Analyses
Characteristic
Persistent
Non-persistent
Odds Ratio
(N = 357)
(N = 44)
(95% CI)
% (n)
% (n)
89.45 (178)
10.55 (21)
Reference
Not Hospitalized
89.05 (179)
10.95 (23)
0.918 (0.491 - 1.719)
Hospitalized
Days' Supply
<60 days
>60 days
Age, years

Gender
Male
Female

% (n)
90.48 (323)
9.52 (34)

% (n)
61.36 (27)
38.64 (17)

Mean Age [SD]
57.20 [7.25]
57.16 [8.58]
% (n)
67.23 (240)
32.77 (117)
(n)

%

(n)

P Value
0.978
Odds Ratio (95% CI)
Reference
1.162 (0.586 -2.304)
Odds Ratioa (95% CI)

Comorbid
Diseasesa
Asthma/COPD
CVD
Mental Health

10.64 (38)
22.41 (80)
12.61 (45)

13.64 (6)
22.73 (10)
13.64 (6)

0.754 (0.299 - 1.901)
0.982 (0.465 - 2.074)
0.913 (0.365 - 2.283)

Diabetes Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use

% (n)
5.60 (20)
33.89 (121)
36.41 (130)
24.09 (86)

% (n)
11.36 (5)
25.00 (11)
38.64 (17)
25.00 (11)

Odds Ratio (95% CI)
Reference
2.750 (0.864 - 8.756)
1.912 (0.635 - 5.759)
1.955 (0.610 - 6.258)

Regimen
Complexity

Mean Number [SD]
9.49 [4.40]
9.98 [3.80]
% (n)
% (n)
15.97 (57)
6.82 (3)
29.97 (107)
34.09 (15)
32.77 (117)
31.82 (14)
21.29 (76)
27.27 (12)

P Value
0.434
Odds Ratio (95% CI)
Reference
2.663 (0.740 - 9.582)
2.273 (0.628 - 8.227)
2.999 (0.809 -11.125)

<6 Medications
6-8 Medications
9-12 Medications
12< Medications

%

% (n)
70.45 (31)
29.55 (13)

Odds Ratio (95% CI)
Reference
0.167* (0.083 - 0.337)

Comorbidity
% (n)
% (n)
Odds Ratio (95% CI)
Indexb
CMI Score = 0
59.09 (26)
52.38 (187)
Reference
CMI Score = 1
13.64 (6)
11.48 (41)
0.950 (0.367 - 2.456)
CMI Score = 2
15.91 (7)
17.09 (61)
1.212 (0.501 -2.930)
CMI Score > 3
11.36 (5)
19.05 (68)
1.891 (0.698 - 5.122)
a
Reference is the absence of the comorbidity
b
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant. Pearson chi-square test was used for all categorical comparisons and the
independent t-test for continuous variables with equal variance or Satterthwaites approximate ttest if variance was unequal
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Multivariable Logistic Regression Model: ACE Inhibitor/ARB Cohort
The results of a multivariable logistic regression analysis of the effect of hospitalization on
persistence with ACE inhibitor/ARB therapy, adjusted for relevant confounders and interaction terms,
are presented in Table 3. Collinearity was not found between any of the independent variables assessed
for inclusion into this model. A single interaction term between the risk factor (hospitalization) and
cardiovascular disease met criteria and was included in the final model. After adjusting for all potential
confounders and the interaction between hospitalization and cardiovascular disease, the beta coefficient
representing the relationship between hospitalization and persistence was significant (-0.931
[P=0.0283]). Due to the inclusion of an interaction term in the model, the odds of persistence in
hospitalized patients relative to non-hospitalized patients are presented separately for individuals with
and without cardiovascular disease. Patients that were hospitalized and had cardiovascular disease had
an increased odds of persistence relative to patients that were not hospitalized that had cardiovascular
disease (2.052 [0.384-10.972)]. Patients that were hospitalized and did not have cardiovascular disease
were significantly less likely to persist compared with patients that were not hospitalized and did not
have cardiovascular disease (0.394 [0.171-0.906]). The only other significant term in the final model
was the duration of prescription supply. Patients receiving a prescription supply of greater than 60 days
were less likely to have persisted (0.127 [0.056-0.287]) compared with those with a supply of 60 days
or less.
Assessment for confounding involved comparison of the beta coefficient and P-value for
hospitalization from the final model with the beta coefficient and P-value obtained from a reduced
model absent the potential confounder of interest. A substantial change upon variable removal was
indicative of confounding. Duration of prescription supply impacted a large magnitude change in the
beta coefficient upon removal from the model. Prescription supply was also significantly associated
with hospitalization, and as a result was identified as a confounder. Through this same process, the
diabetes regimen and medication regimen complexity variables were also identified as confounders.
The inclusion of all other variables in the model was determined necessary to adjust for differences in
baseline characteristics and due to clinical importance.
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Table 3
Influence of Hospitalization on Persistence with ACE Inhibitor/ARB Therapy:
Results of a Multivariable Logistic Regression Model
Characteristic
Beta
Standard
Odds Ratio (95% CI)
Coefficient
Error
Not Hospitalized
Reference
Hospitalized
-0.931*
0.425
Hospitalized (Cardiovascular disease)a
2.052 (0.384 - 10.972)
Hospitalized (No cardiovascular disease)a
0.394* (0.171 - 0.906)
Days' Supply
<60 days
>60 days

-2.067*

0.418

Odds Ratio (95% CI)
Reference
0.127* (0.056 - 0.287)

0.580
1.000

0.470
0.529

Odds Ratio (95% CI)
Reference
1.787 (0.711 - 4.491)
2.719 (0.963 - 7.675)

0.057

0.393

Odds Ratio (95% CI)
Reference
1.058 (0.490 - 2.288)

0.570
-0.936
-0.624

0.751
0.689
-0.624

Odds Ratio (95% CI)
1.769 (0.406 - 7.700)
0.392 (0.10 - 1.515)
2.044 (0.532 - 7.846)
0.536 (0.191 - 1.507)

1.364
0.0572
0.693

0.722
0.631
0.705

Odds Ratio (95% CI)
Reference
3.912 (0.950 - 16.100)
1.059 (0.307 - 3.648)
1.999 (0.502 - 7.957)

0.785
0.989
1.007

0.572
0.567
0.642

Odds Ratio (95% CI)
Reference
2.193 (0.715 - 6.720)
2.689 (0.885 - 8.163)
2.736 (0.777 - 9.637)

Age, years
Age < 59
59 < Age <63
63 < Age
Gender
Male
Female
Comorbid Diseasesb
Asthma/COPD
Cardiovascular
Cardiovascular (Non-hospitalized)c
Cardiovascular (Hospitalized)c
Mental Health
Diabetes Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use
Regimen Complexity
<6 Medications
6-8 Medications
9-12 Medications
12< Medications
Comorbidity Indexd

Odds Ratio (95% CI)
CMI Score = 0
Reference
CMI Score = 1
0.138
0.598
1.148 (0.356 - 3.704)
CMI Score = 2
0.575
0.591
1.777 (0.558 - 5.661)
CMI Score > 3
-0.572
0.552
0.564 (0.191 - 1.663)
a
Interaction of hospitalization and cardiovascular disease included in model, odds of persistence for
hospitalized relative to non-hospitalized patients reported with and without cardiovascular disease
b
Reference is the absence of the comorbidity
c
Odds of persistence for patients with/without cardiovascular disease by hospitalization status
d
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant at < 0.05
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Multivariable Logistic Regression Model: Lipid Lowering Drug Cohort
The results of a multivariable logistic regression analysis of the effect of hospitalization on
persistence with lipid lowering drug therapy, adjusted for relevant confounders and interaction terms,
are presented in Table 3a. Collinearity was not found between any of the independent variables assessed
for inclusion into this model. There were no interaction terms that met criteria for inclusion into the
final model. The odds of persistence did not differ between hospitalized patients and non-hospitalized
patients (0.961 [0.469-1.972]). Patients receiving a prescription supply of greater than 60 days were
much less likely to persist (0.146 [0.068 - 0.313]) relative to patients with a supply of less than or equal
to 60 days. Patients utilizing medication to treat diabetes had an increased odds of persistence compared
to patients not on drug therapy, regardless of whether it was monotherapy, polytherapy or any regimen
containing insulin. The increased odds of persistence achieved statistical significance for patients using
monotherapy (3.765 [1.064-13.324]). A consistently lower likelihood of persistence was observed in the
three groups of patients with greater regimen complexity (6-8, 9-12, 12< medications) relative to those
using 5 medications or less during the baseline period, but this result did not achieve statistical
significance.
A confounding assessment was carried out using the process described for the ACE
inhibitor/ARB model. Duration of prescription supply caused a large magnitude change in the beta
coefficient upon removal from the model. The negative association between prescription supply and
hospitalization approached significance (P = 0.088), as a result prescription supply was identified as a
confounder. Through this same process, the diabetes regimen and medication regimen complexity
variables were both identified as confounders. The inclusion of all other variables in the model was
determined necessary to adjust for differences in baseline characteristics and due to clinical importance.
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Table 3a
Influence of Hospitalization on Persistence with Lipid Lowering Drug Therapy Adjusted
for: Prescription Supply Duration, Age, Gender, Comorbid Disease Burden, Diabetes
Medication Regimen and Number of Medications Used
Results of a Multivariable Logistic Regression Model
Characteristic

Beta Coefficient

Standard Error

Odds Ratio
(95% CI)

-0.040

0.367

Reference
0.961 (0.469 - 1.972)

Days' Supply
<60 days
>60 days

Beta Coefficient
-1.926*

Standard Error
0.389

Odds Ratio (95% CI)
Reference
0.146* (0.068 - 0.313)

Age, years
Age a

Beta Coefficient
0.006

Standard Error
0.024

Odds Ratio (95% CI)
1.006 (0.959 - 1.055)

Gender
Male
Female

Beta Coefficient
0.071

Standard Error
0.380

Odds Ratio (95% CI)
Reference
1.074 (0.509 - 2.262)

Comorbid Diseasesb
Asthma/COPD
Cardiovascular
Mental Health

Beta Coefficient
-0.527
-0.018
0.079

Standard Error
0.617
0.437
0.535

Odds Ratio (95% CI)
0.591 (0.176 - 1.977)
0.982 (0.417 - 2.312)
1.082 (0.379 - 3.086)

Diabetes Regimen
No Drug Therapy
Monotherapy
Polytherapy
Any Insulin Use

Beta Coefficient
1.326*
1.121
1.199

Standard Error
0.645
0.623
0.678

Odds Ratio (95% CI)
Reference
3.765* (1.064 - 13.324)
3.068 (0.907 - 10.378)
3.316 (0.878 - 12.520)

Regimen Complexity
<6 Medications
6-8 Medications
9-12 Medications
12< Medications

Beta Coefficient
-1.205
-1.071
-1.279

Standard Error
0.694
0.712
0.770

Odds Ratio (95% CI)
Reference
0.299 (0.077 - 1.167)
0.343 (0.085 - 1.382)
0.278 (0.062 - 1.259)

Not Hospitalized
Hospitalized

Comorbidity Indexc
Beta Coefficient
Standard Error
CMI Score = 0
CMI Score = 1
0.417
0.615
CMI Score = 2
0.495
0.505
CMI Score > 3
0.917
0.601
a
Age variable coded as continuous
b
Reference is the absence of the comorbidity
c
Charlson comorbidity index48 with updated weighting from Quan et al49
*
P value is significant
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Odds Ratio (95% CI)
Reference
1.517 (0.454 - 5.064)
1.640 (0.610 - 4.412)
2.501 (0.770 - 8.129)

Therapeutic Duplication
Therapeutic duplication occurred infrequently with both medication classes regardless of
exposure status. Of the 189 hospitalized patients that were only using a single ACE inhibitor or ARB
during the baseline period, 3 (1.59%) duplicated therapy during the post-hospitalization period.
Similarly, of the 186 non-hospitalized patients that were using a single drug during the baseline period,
1 patient (0.54%) duplicated therapy during the follow-up period. Of the 186 hospitalized patients that
had 2 or more claims for a statin during the baseline period, 1 patient (0.54%) duplicated therapy. A
total of 3 (1.63%) non-hospitalized patients duplicated statin therapy of the 184 that had 2 or more
claims for a statin during the baseline period.
Time to Primary Care Physician Visit
The number of patients persisting was similar between patients with a shorter (<12 days) time
until a follow up visit with a primary care provider compared with patients with a longer (12< days)
time until follow up for both ACE inhibitors/ARBS (P=0.537) and for LLDs (P=0.786) (Table 4 and
Table 4a).
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Table 4

Influence of Time to Follow Up with a Primary Care
Provider on Post Discharge Persistence in Hospitalized
Patients Using ACE Inhibitors/ARBs
Time Until Follow Upa
Persistent
Non-Persistent
N = 97
N = 104
% (n)
% (n)
<12 days
12< days

47.46 (84)
52.54 (93)

54.17 (13)
45.83 (11)

a

P Value

0.537

The median time until follow up with a primary care physician was 12 days; 19 patients did not
follow up within the 60 day period and were grouped with the patients that had a time until follow
up of 12< days
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Table 4a

Influence of Time to Follow Up with a Primary Care
Provider on Post Discharge Persistence in Hospitalized
Patients Using Lipid Lowering Drug Therapy
Time Until Follow Upa
Persistent
Non-Persistent
N = 179
N = 23
% (n)
% (n)
<12 days
12< days

50.84 (91)
49.16 (88)

47.83 (11)
52.17 (12)

a

P Value

0.786

The median time until follow up with a primary care physician was 12 days; 19 patients did not
follow up within the 60 day period and were grouped with the patients that had a time until follow
up of 12< days
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CHAPTER 4

DISCUSSION

Transitions of care present a particularly vulnerable time for patients. Inadequate
communication both between providers and with the patient has the potential to introduce inaccuracies
into the medication regimen and precipitate inappropriate medication taking behavior. Consequent
adverse drug events are often preventable, and contribute to increased healthcare utilization and
expenditures. The IOM report "Preventing Medication Errors" emphasized transitions of care as an area
that requires substantial research to better understand and address the incidence of medication errors.2
Institutions, clinicians and professional organizations, amongst others, have since mobilized in an effort
to determine what patient populations are at the greatest risk and what interventions are most effective
for improving patient safety.
The present study investigated the potential of hospitalization to disrupt continuity of
appropriate medication use by comparing persistence with evidence based chronic medications between
hospitalized and non-hospitalized patients with diabetes. An increased likelihood of inappropriate
discontinuation was hypothesized for hospitalized patients using medications within both classes
studied, ACE inhibitors/ARBs and LLDs. The effect of hospitalization on persistence [Beta estimate (Pvalue)] was not consistent between these two medication classes, as hospitalization was a significant
risk factor for non-persistence with ACE inhibitors/ARBs [-0.931 ( P=0.028)] but there was no effect on
the odds of persistence with LLDs [-0.036 (P=0.922)]. The significant negative effect of the risk factor
of interest on the odds of ACE inhibitor/ARB persistence [Odds ratio (95% CI)] was modified by the
presence [2.052 (0.384-10.972)] or absence [0.394 (0.171-0.906)] of cardiovascular disease. Without
inclusion of the interaction between hospitalization and cardiovascular disease in the multivariable
model, hospitalization was no longer a significant risk factor for non-persistence (Appendix F). The
bivariate models for each medication class supported the lack of association between hospitalization
and LLD persistence [0.918 (0.491-1.719)] and the mitigated relationship between hospitalization and
ACE inhibitor/ARB persistence [0.733 (0.385-1.398)].
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We also investigated hospitalization as a possible risk factor for inappropriate duplication of
therapy with both classes of study medications. The low frequencies of duplication observed [(ACE
inhibitor/ARB:1.59% hospitalized, 0.54% non-hospitalized); (LLD: 0.54% hospitalized, 1.63% nonhospitalized)] precluded bivariate and multivariable analysis for this outcome. Therapeutic duplication
was found to be infrequent in this population due to a confluence of factors. To reduce the likelihood of
misclassification, duplication was only assessed for statins as a subclass of the broader class of LLD.
The use of multiple LLDs may be therapeutically indicated, whereas the use of more than 1 statin is not
appropriate in any clinical situation. Similarly, patients that filled multiple ACE inhibitor/ARB
prescriptions during the baseline 180 days were excluded from the duplication analysis during the
follow up period. It was not possible to determine if the use of multiple drugs from this class was
therapeutically appropriate during the baseline period. Other contributors to the observed low frequency
of duplication may be the ease of detection for healthcare providers and the use of decision support
software that would flag the prescription prior to dispensing. It is also possible that patients were
duplicating therapy at home from previously dispensed prescriptions, in which case we would be unable
to detect such inappropriate medication usage.
The duration of prescription supply emerged as a significant confounder of the association
between hospitalization and persistence. The number of patients that received a prescription supply of
greater than 60 days for a study medication during the baseline period was unevenly distributed
between the hospitalized and non-hospitalized groups. In the bivariate and multivariable analyses, a
supply duration of greater than 60 days increased the odds of non-persistence for ACE inhibitors/ARBs
and LLDs. This phenomenon may be explained by continued use of a 90 day prescription that was filled
before hospital admission, or in matched patients, the sustained use of a 90 day prescription that was not
due for a refill during the follow up period. In either case, patients would be at risk for being
misclassified as non-persistent despite appropriate use of the study medication. Inclusion of the days'
supply variable in the final model was essential in order to adjust for the effect of supply duration,
which if left unadjusted would have obscured the effect of hospitalization on non-persistence. In
contrast, therapeutic duplication is more likely to have been underestimated as a result of
misclassification in this study. Patients choosing to continue taking a medication prescribed prior to
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hospitalization, in addition to another medication within the same class prescribed upon discharge,
would be inappropriately duplicating therapy. Such duplication is not detectable unless the patient
refills the original prescription during the follow up period, which may not be necessary if the original
supply was for greater than 60 days.
Evaluations of real-world medication usage by patients apply the terms adherence (synonym:
compliance) and persistence to describe two separate constructs.30 Other terms have been used to
describe persistence (discontinuation rates, continuous adherence, persistency, time of continuous
adherence), and reports have frequently stated that the endpoint under investigation was persistence
when it was in fact adherence and vice versa. Medication adherence is the act of conforming to the
recommendations of the provider with respect to timing, dosage, and frequency of medication taking.
Medication persistence refers to the duration of time from initiation to discontinuation of therapy.30 In
our study, the outcome of persistence was dichotomized and patients were categorized as persistent or
non-persistent depending on the presence or absence of a prescription claim indicating therapy
continuation during a pre-specified period of time. All patients were required to have at least two claims
during the baseline period prior to the index hospitalization, and a third claim during the follow up
period was indicative of continued use of the medication (persistence).
The healthy adherer effect postulates that improved clinical outcomes in adherers to drug
therapy compared with non-adherers is not entirely attributable to the benefits of the medication.50
Instead, adherence to medication is a surrogate marker for overall healthy behavior, which introduces
bias if left unaccounted for in an analysis of drug effect.51 The effects of healthy adherers are not
evident in our results, but a separate construct that influences medication taking behavior may be
implicated.
Consistent with our hypothesis, hospitalization disrupted medication use for patients without
cardiovascular disease. In contrast to our hypothesis, patients with a history of cardiovascular disease
that were hospitalized were more likely to persist relative to patients with cardiovascular disease that
were not hospitalized. This latter finding aligns with the tenants of the 'Necessity-Concerns Framework'
conceptual model for understanding patient's perspectives on prescribed medicines.46 A meta-analysis
of 94 studies assessed the utility of this model, determining that better adherence to medications for
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chronic disease was associated with stronger perceptions of the necessity of treatment [Pooled OR
1.742 (95% CI 1.569-1.934)] and fewer concerns about potential adverse effects of treatment [Pooled
OR 0.504 (95% CI 0.450-0.564)].46 Recently hospitalized patients with diabetes and comorbid
cardiovascular disease may be more likely to perceive the necessity of treatment with antihypertensive
medications and overlook concerns about adverse effects, contributing to the results observed in our
study.
Factors associated with medication persistence are dependent upon the characteristics of the
patient population, the medication class, and the data source being evaluated. A study of persistence by
Gregoire et al prospectively recruited 692 patients presenting to 173 pharmacies in Ontario, Canada,
with a new prescription for an antihypertensive medication from 1 of 3 classes including ACE
inhibitors, ARBs, and calcium channel blockers.52 Data were collected through a structured
questionnaire during a telephone interview within five days of study entry, and again at 1 month, 3
months, and a fourth time between 18 and 32 months after enrollment. The results of a multivariate
hazard model determined that the likelihood of non-persistence was greater in patients that lacked
insurance coverage (odds of discontinuation in patients with any insurance coverage of 0.74; 95% CI
0.53-0.97), reported medication side effects (OR 1.91; 95% CI 1.47-2.47), or reported a belief of no
drug effect (OR 1.29; 95% CI 0.97-1.71). The proportion of patients discontinuing therapy was 11.9%
at 1 month, 23.8% at 3 months, and 43.3% based upon the last observation for each individual within
the study period. Of these patients that were no longer on the original therapy, 32.3% had changed to
another antihypertensive drug and 11% were no longer receiving drug treatment for hypertension. The
survey based design was advantageous for detecting the influence of patient beliefs about drug effects
on persistence, but the results of this study are also limited by the accuracy of the surveyed patient's
responses and the intervals of time between survey administration.52
Jackevicius and colleagues assessed primary medication non-adherence to newly prescribed
medications at discharge from a hospitalization due to acute myocardial infarction (AMI).53 A
retrospective cohort study was performed utilizing AMI registry data of patients from 104 hospitals in
Canada. Registry data were linked to prescription claims, vital statistics, physician services, and
hospital discharge databases. Patients included were at least 66 years of age upon discharge and had an
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ICD-9 code for AMI. The primary outcome was death within 1 year after discharge. Primary adherence
(the risk factor of interest) was categorized as all medications, some medications, or no medications
filled within 120 days after the discharge date. Discharge prescriptions written for ACE inhibitors were
not filled within 120 days in 3.82% of patients, while prescriptions for statins were not filled in 5.15%
of patients within 120 days. Fill rates of non-cardiac medications that were assessed in this study were
substantially lower than fill rates for cardiac medications (34.6% vs 82.3%; P<0.0001). A significantly
increased risk of death was observed in patients that failed to fill all (OR 1.80; 95% CI 1.35-2.42) or
some medications (OR 1.44; 95% CI 1.15-1.79) prescribed at discharge relative to patients that filled all
prescriptions within 120 days. Receipt of pre-discharge counseling was associated with a reduced
likelihood of death within 1 year (OR 0.71; 0.58-0.87). In this study prescription data was not available
from private insurers and as a result only elderly patients were included. Rates of primary nonadherence following hospitalization for AMI were low, but these results are unlikely to represent
younger or commercially insured populations.53
The findings by Gregoire et al and Jackevicius et al reinforce the proposed connection between
patient perceptions of medication efficacy and the necessity for compliance and persistence with
therapy.52-53 In the survey study by Gregoire et al both patient perceived absence of drug effectiveness
and the occurrence of adverse effects attributed to the drug were associated with significantly lower
persistence.52 Instead of directly reported perceptions, patients in the study by Jackevicius et al were
retrospectively selected based upon recent hospitalization specifically for AMI.53 The finding of
substantially higher primary adherence rates with cardiac medications follows directly from the
recognition of elevated cardiac risk that would be anticipated in patients following a hospitalization for
AMI. Insurance coverage, a predictor of persistence identified by Gregoire,52 was not a factor in our
study since all patients were confirmed to be enrolled with the same commercial insurer. Additional
covariates that were not associated with changes in persistence including age, gender, and comorbid
disease burden were evaluated and yielded concordant results with those obtained in our present
research.52 Identification of patients that received pre-discharge counseling, a predictor of persistence in
the study by Jackevicius,53 was not possible with our commercial claims data source.
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Long term use of evidence based, guideline recommended oral therapies for heart failure has
been shown to reduce morbidity and mortality.54 The Get With The Guidelines-Heart Failure program is
an ongoing, prospective, observational data collection and quality improvement initiative that collects
information on medical history, hospital care and clinical outcomes.55 Krantz et al assessed the inpatient
patterns of use and continuation of ACE inhibitors/ARBs, aldosterone antagonists, and beta blockers
while also determining predictors of use.56 Patients included for evaluation had reduced ejection
fraction (EF<40%) heart failure and were admitted to hospitals participating in the program across the
United States. In patients with no contraindication to therapy, the proportion of patients using ACE
inhibitors/ARBs, beta blockers, and aldosterone antagonists at admission was 65.3%, 72.6% and 15.6%,
respectively. The proportion of patients using ACE inhibitors/ARBs, beta blockers, and aldosterone
antagonists at discharge was 92.9%, 90.1% and 26.2% respectively. Of the population of patients that
were already receiving ACE inhibitors/ARBs at hospital admission, 2.6% did not persist with the
medication at discharge. The strongest predictors of ACE/ARB usage at discharge were medication
usage at admission (OR 7.4; 95% CI 4.6-11.8), the absence of concomitant renal insufficiency (OR 2.7;
95% CI 2.1-3.4), and the absence of concomitant hypertension (OR 1.34; 95% CI 1.02-1.77). These
results are limited by the lack of available persistence data for the period following hospital discharge.56
In the study by Krantz et al patients with heart failure that were taking ACE inhibitors/ARBs
upon admission into the hospital were more than 7 times as likely to be discharged on the medication
compared with patients admitted that were not receiving a drug from this class.56 Our study design
included only patients that were confirmed to be using a medication from a study drug class prior to a
hospital admission. We observed a proportion of patients with cardiovascular disease that did not persist
with ACE inhibitor/ARB therapy of 10.26%, which was much larger than the 2.6% that did not persist
in the study by Krantz et al.56 Much of this difference can likely be explained by the definition of
persistence, which was measured at discharge by Krantz and did not require confirmation of a
prescription dispensing after the patient left the hospital.56 Although persistence patterns with statins
were not assessed in this population of heart failure patients, we found a comparable rate of nonpersistence with statins in patients with cardiovascular disease of 10.11%.
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Quality of care measures provided prior to hospitalization have been shown to impact 30 day
re-hospitalization rates in a nationally representative population of commercially insured adult patients
with diabetes.57 Chen et al evaluated data from the IMS Lifelink Database to determine if receipt of 2 or
more HbA1c tests, 1 or more LDL tests, at least 90 days of a statin supply dispensed, or at least 90 days
of an ACE inhibitor/ARB supply dispensed in the year preceding a hospitalization reduced the odds of
readmission within 30 days of discharge.57 In a multivariate logistic regression model that adjusted for
patient demographic and comorbid disease characteristics, odds of readmission were significantly
decreased with the receipt of at least 1 LDL test (OR 0.92; 95% CI 0.85-0.99) or receipt of at least 90
days of a statin prescription (OR 0.91; 95% CI 0.85-0.97). Odds of readmission were marginally
decreased with at least 90 days of an ACE inhibitor/ARB prescription (OR 0.94; 95% CI 0.88-1.01) or
with receipt of at least 2 HbA1c tests (OR 0.94; 95% CI 0.87-1.02). The impact of the performance of
quality of care measures preceding a hospitalization on readmission rates demonstrated in this study
was limited by the lack of persistence data following discharge and the absence of a comparator group
of non-hospitalized patients.57
Bell et al recently evaluated the risk of unintentional discontinuation of medications prescribed
to treat chronic disease in patients undergoing 1 or more transitions of care.6 Similar to the study by
Jackevicius,53 this study utilized linked prescription claims, vital statistics, physician services, and
hospitalization databases to identify elderly patients (age > 66) admitted to all acute care hospitals in
Ontario, Canada.6 Patients were required to be continuous users for at least 1 year of at least 1
medication from 5 medication classes: statins, antiplatelets/anticoagulants, levothyroxine, respiratory
inhalers, and gastric acid suppressants. Exposure was categorized into three groups: non-hospitalized
patients (unexposed), hospitalized patients (1 transition of care), and hospitalized patients that spent
time in the ICU (2 transitions of care). The primary outcome of interest was the absence of a
prescription renewal for a drug from within the original medication class in the 90 days following the
index date (the date of discharge for hospitalized and a randomly assigned date for non-hospitalized
patients). Compared with non-hospitalized patients the odds of unintentional discontinuation were
increased in hospitalized patients without an ICU stay [(statins: OR 1.33; 95% CI 1.29-1.37),
(antiplatelets/anticoagulants: OR 1.86; 95% CI 1.77-1.97), (levothyroxine: OR 1.18; 95% CI 1.14-1.23),
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(respiratory inhalers: OR 1.50; 95% CI 1.15-1.97), and (gastric acid suppressants: OR 1.50; 95% CI
1.43-1.56)] and increased further in hospitalized patients with an ICU stay [(statins: OR 1.48; 95% CI
1.39-1.57), (antiplatelets/anticoagulants: OR 2.31; 95% CI 2.07-2.57), (levothyroxine: OR 1.51; 95% CI
1.38-1.66), (respiratory inhalers: OR 1.84; 95% CI 1.10-3.08), and (gastric acid suppressants: OR 1.87;
95% CI 1.71-2.05)]. The composite secondary outcome of death, emergency department visit, or
emergent hospitalization during a period of 91 days to 365 days post discharge was more likely to occur
in patients that discontinued statins (OR 1.07; 95% CI 1.03-1.11) or antiplatelets/anticoagulants (OR
1.10; 95% CI 1.03-1.16) within the 90 days after discharge. These results provide valuable context for
the relationship between non-persistence and adverse health outcomes in a large representative
population of elderly adults following a hospitalization. Risk for adverse events following
discontinuation was not equal between medication classes, with the greatest risk observed in
medications used for the prevention of macrovascular events.6
Improving outcomes following a hospitalization, including reducing 30 day readmission rates,
has become an incentivized priority with the implementation of the Affordable Care Act.58
Underperforming hospitals with increased readmission rates for certain disease states relative to other
similar institutions are subject to reduced reimbursement.58 The results presented by Chen suggest that
adherence to recommended processes of care for commercially insured patients with diabetes will
positively influence 30 day readmission rates.57 Bell and colleagues demonstrated that appropriate use
of chronic medications in elderly patients is disrupted incrementally by 1 or more transitions of care.
Furthermore, non-persistence following a hospitalization with medications for the prevention of adverse
macrovascular outcomes (statins, antiplatelets/anticoagulants) placed elderly patients at an increased
likelihood for 1 year mortality and rehospitalization.6 Our study evaluated a commercially insured
population, similar to Chen,57 but persistence after a hospitalization was measured with medication
classes used for the prevention of micro and macrovascular outcomes, similar to Bell.6 Considering
these relevant findings, our results indicate that patients with diabetes and comorbid cardiovascular
disease that were not hospitalized, as well as patients hospitalized without cardiovascular disease, may
also be at an increased risk of adverse health outcomes due to lower rates of persistence. Further studies
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designed to follow persistence patterns and evaluate health outcomes are necessary in patients with
diabetes.
Based upon our multivariable model, certain populations of LLD users are possibly at greater
risk of unintentional discontinuation of LLD therapy. A non-significant trend was observed for
decreasing comorbid disease burden associated with increasing odds of non-persistence (Table 3a).
Similarly, patients without documented use of a medication for diabetes treatment during the baseline
period were the least likely to persist with LLD therapy. An opposite tendency was demonstrated with
regards to regimen complexity. In agreement with our hypothesis, patients using the least number of
medications during the baseline period had the greatest relative likelihood of persisting. These
conflicting phenomena are presumed to be the consequence of multiple contributing factors and random
variation. Healthier patients with diabetes that were not using hypoglycemic medication and had a
minimal burden of comorbid disease may not have perceived LLD treatment as necessary and were
consequently at an increased risk for non-persistence. In addition to polypharmacy, the regimen
complexity variable may have captured a separate indicator of disease burden that was not fully
reflected in the comorbidity score grouping and was associated with an increased risk for nonpersistence. Ultimately the main result of the LLD multivariable analysis was that after adjusting for all
possible confounders, there was no difference in odds of persistence between non-hospitalized and
hospitalized patients with diabetes (0.961 [0.469 - 1.972]).
Studies evaluating relative rates of mortality and other adverse health outcomes between
adherent/persistent patients with non-adherent/non-persistent patients have demonstrated that
appropriate usage of statins and ACE inhibitors/ARBs is associated with better clinical outcomes.6-7, 3338

This result should be expected when these drugs are used for evidence based indications in patient

populations for which expert professional organizations have published guidelines recommending their
use.40-41, 54 A more difficult question involves the determination of what level of patient adherence is
necessary to achieve the beneficial effects of the medication before a difference in clinical outcomes is
manifested. This uncertainty applies indirectly to persistence. When the definition of persistence is
established for a study protocol, it is necessary to identify what period of time must elapse between the
dispensing of two prescriptions that is indicative of non-persistence. A longer permissible gap will
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directly translate into a lower acceptable level of adherence that is necessary to remain persistent. In our
present study, a period of 60 days without a prescription claim for the medication was used. Assuming a
30 day prescription supply (87.31% of the LLD cohort, 85.04% of the ACE inhibitor/ARB cohort), if
the patient filled a prescription immediately prior to the beginning of the 60 day follow-up period then
an adherence level of 50% would be sufficient to last the 60 days without another prescription fill. An
adherence level greater than 50% would result in a refill during this period confirming persistence, but
the proportion of therapeutic effect achieved by a persistent patient with reduced adherence remains
uncertain.
Rasmussen et al addressed the problem of relative risk for incremental levels of adherence in a
population of elderly adults (age >66) in Ontario, Canada, following a hospitalization for AMI.33 For
inclusion into the study, all patients were required to fill a prescription for either a statin, beta-blocker,
or calcium channel blocker in the 3 months after hospital discharge. In the year following dispensing of
the first study medication, the proportion of days covered (PDC) was determined and levels of
adherence were subdivided into 3 categories (high adherence: PDC > 80%; intermediate adherence:
PDC > 40%-79%; and low adherence: PDC > 40%). The primary outcome of long term mortality was
assessed over a median period of 2.4 years. Non-persistence was determined over the full period of
follow up and defined as the absence of an expected prescription based upon previous quantities
supplied, evaluated over 6 month periods from each previous prescription dispensing. Non-persistence
at the end of follow up was 13.2%, 19.6% and 33.5% for statins, beta blockers, and calcium channel
blockers, respectively. A dose-response type relationship was observed with the risk of mortality (HR;
95% CI) increasing with decreasing levels of adherence with statins [(intermediate adherence: 1.12;
1.01-1.25), (low adherence 1.25; 1.09-1.42)] and beta blockers [(intermediate adherence: 1.01; 0.931.09), (low adherence 1.13; 1.03-1.25)]. This relationship was stronger with statins than with beta
blockers, and was not detected with calcium channel blockers. The absence of an adherence-mortality
relationship for calcium channel blockers, a medication class which does not have any proven post-AMI
survival advantages, supports the attribution of a survival benefit for the other medication classes to
drug effect rather than the healthy adherer effect. 33
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Recognition of the detrimental outcomes occurring secondary to inappropriate management of
the medication regimen during care transitions has lead to the development and evaluation of numerous
institution specific interventions.15-16 Due to the fragmented nature of the United States health system
and the logistical difficulties in organizing large multi-site trials, stakeholders have typically
approached the issue individually as it directly relates to a specific practice population, professional
discipline, or institution. Individualized programs targeting care transitions have involved a multitude of
different healthcare providers including nurses,17-19 physicians,20 pharmacists,17-19,21-23 pharmacy
technicians,24,28 and nurse practitioners.25-26 Examples of interventions include medication reconciliation
at admission and or discharge, post discharge phone calls or home visits, motivational coaching and
education, or a combination of multiple interventions.17-28 These interventions have yielded varying
degrees of success on clinical and surrogate outcomes, with limited generalization to larger populations.
Care transition interventions are often compared with the standard of care provided prior to
implementation of the intervention at the institution.20, 23-25 A systematic review of the literature by
Kripalani et al sought to characterize the types and prevalence of deficits in communication between
hospital based and community based physicians at hospital discharge.20 A total of 55 observational
studies that had been published from 1970 through 2005 were included. In these studies, 3% of primary
care physicians reported being involved in discussions about discharge and 17-20% reported always
being notified of discharges. Within 1 week of discharge, a median of 53% (30-94%) of discharge
letters and 14.5% (9-20%) of physician dictated discharge summaries had reached the primary care
physician. In addition, 11% of discharge letters and 25% of discharge summaries never reached the
primary care physician. Interventional studies included in the review involved either provision of
computer generated and manually created discharge summaries, changes in the mode of information
delivery, or reformatting of the discharge documents. No standardized measures were used across
studies, and results indicated a mix of significant and non-significant improvements in timeliness of
discharge communication. This systematic review of the literature emphasizes the historical
inefficiencies of hospital physician to outpatient physician communication and the limited application
of institution specific interventions for broader health system improvement.20
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Pharmacist intervention during care transitions has demonstrated varying levels of success. 1719,21-23

A randomized controlled trial that assessed pharmacist counseling at discharge was carried out at

a single academic hospital in Boston, Massachusetts.18 Routine care involved the review of medication
orders by the ward based pharmacist and discharge counseling provided by a nurse, which sometimes
consisted of informal medication reconciliation. The multifaceted pharmacist intervention consisted of
evaluation for previous drug related problems (side effects, non-adherence), reconciliation of discharge
medications with admission medications, and the review of discharge medications with the patient. A
follow-up phone call 3 to 5 days after discharge was also performed by the pharmacist. During the
phone call, medication use by the patient was reconciled with discharge medication instructions and
adherence to post hospital care was assessed and communicated to the outpatient primary care
physician. A significant reduction in preventable ADE's (1% intervention vs 11% usual care; P=0.01)
was observed at 30 days post discharge. The total number of ADEs and resource utilization was similar
between groups, but the number of preventable medication related emergency department visits and
readmissions was reduced in the intervention group (1% vs 8%; P=0.03). Pharmacists are capable of
performing medication reconciliation, and were shown to beneficially impact post discharge medication
use. The small number of patients participating in the trial and the short period of follow up may have
limited the ability to demonstrate an overall reduction in ADEs and resource utilization.18
Another randomized controlled study conducted at an academic hospital in Boston,
Massachusetts, achieved improvements in post discharge hospital utilization with coordinated discharge
intervention by a nurse and pharmacist.19 A nurse discharge advocate arranged follow up appointments,
reconciled medications with outpatient records, and conducted inpatient education. The pharmacist
performed follow-up phone calls in the week post discharge to perform a medication review and
subsequent corrective action as needed. Compared to usual care, the 30 day combined re-hospitalization
and emergency department visit rate was reduced (incident rate ratio: 0.695; 95% CI 0.515-0.937). The
proportion of patients following up with their primary care provider after discharge was significantly
greater in the intervention group (62% vs 44%; P=0.007). The nurse discharge advocate spent an
average of 87.5 minutes, and the pharmacist an average of 26 minutes, per patient providing
intervention related services. A cost analysis considering the cost of follow up appointments and
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hospitalization determined that an estimated $412 per person was averted in the intervention group
compared with usual care. This estimation was limited since it did not account for the cost of the
intervention, although it was determined that the intervention could be partially implemented using the
present hospital employee structure. The authors concluded that in a traditional fee for service model,
the additional services provided by the intervention would not be incentivized through reimbursement
and would be less likely to be implemented than in a capitated or pay-for-performance model.19
Other studies have been unable to demonstrate a clear benefit of pharmacist intervention
during care transitions.21, 23 One randomized controlled study investigated the effect of an integrated
pharmacy discharge plan involving hospital and community pharmacists from 4 hospitals and 29
community pharmacies.23 The intervention involved hospital pharmacist development of medication
and supportive discharge plans for provision to all necessary healthcare providers, as well as a home
follow up visit by a community pharmacist after discharge. The comparison group received usual care,
consisting of a discharge letter to the PCP and no pharmacist pre-discharge medication review. No
significant difference was found with regards to the primary outcome of 6 month readmission between
the control (28.4%) and intervention groups (27.9%). Secondary endpoints measured included
adherence, comprehension, mortality, and healthcare usage. Similar results on the secondary outcomes
were reported for both groups.23
A care transition intervention implemented by Coleman et al utilized strategic patient and
caregiver education.25 The objective of the patient focused intervention was to prepare for future selfmanagement of the medication regimen during care transitions and provider interactions. Community
dwelling elderly adults (age > 65) were recruited upon admission to the study hospital located in
Colorado. A total of 158 patients were included in the intervention and matched to administrative
controls derived from a managed care delivery system with an existing contract with the study hospital.
Patients and their caregivers that received the intervention were provided with tools and support in
order to actively participate in the transition from hospital to home. A geriatric nurse practitioner served
as a transition coach, contacting the patient via telephone and visiting for home visits. The transition
coach performed medication reconciliation during the home visit, and assisted in preparing the patient
for handling future interactions with care providers. The median duration of the intervention for an
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individual patient was 24 days. The primary outcome was the odds of rehospitalization, which was
significantly reduced in the intervention group at 30 days (OR 0.52; 95% CI 0.28-0.96), 90 days (OR
0.43; 95% CI 0.25-0.72) and 180 days (OR 0.76; 95% CI 0.36-0.92) after hospital discharge. The
results of this study are limited by the quasi-experimental design but suggest that an initial investment
in patient education by a specialized transition coach is successful in reducing future resource
utilization. A cost effectiveness evaluation of a similar intervention, evaluated prospectively in a larger
population, would help inform further development of coaching based care transition interventions.25
Inconsistent results have been reported from a multitude of institution or region specific
studies that have evaluated interventions targeting transitions of care.15-26 The importance of
standardization is implicit in the High 5s project presently being implemented internationally by
participant countries within the World Health Organization.27-29 The demonstrable implementation and
evaluation of standardized operating procedures (SOPs) across different cultural, geographic, and
medical care settings involved in this project has been proposed as preferable to the traditional medical
approach of individualized best practice.29 Early results of the SOP for medication reconciliation have
been positive, demonstrating reduced incidence of medication errors upon admission for elderly
patients.27-28 Use of a standardized procedure has contributed to distinct obstacles during
implementation of the SOP.29 Hospitals utilizing pharmacy technicians to obtain a complete medication
history have outperformed hospitals with physician or nursing based models.28 This differential
outcome from the same underlying process draws attention to potential difficulties encountered with a
standardized approach. Expertise is not entirely coincident between practice disciplines and allocation
of responsibility to specific healthcare practitioners will be inconsistent between institutions. The
success of the SOP for medication reconciliation, if sufficiently validated, will still require crossdisciplinary collaboration and tailoring of the SOP to best function within individual practice sites.
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CHAPTER 5

LIMITATIONS AND CONCLUSION

The present study utilized a retrospective matched cohort design to ensure that hospitalized
and non-hospitalized patients were similar with regards to age, gender, comorbidity burden and
enrollment period. The purpose of matching in this study was to ensure that the group of nonhospitalized patients was similar to the group of hospitalized patients. Despite the matching procedure,
a significantly higher percentage of hospitalized patients had diagnoses indicating respiratory and
cardiovascular disease, and mental health disorders. While our multivariate analyses attempted to
control for these differences, it is possible that the effect of hospitalization on medication persistence
was biased by the greater overall disease burden among the hospitalized group. Due to the retrospective,
non-randomized study design and the use of claims data it was not possible to adjust for all possible
confounders. As a result, the potential for uncontrolled residual confounding existed due to additional
variables that may have included but were not limited to socioeconomic status, healthcare service
utilization, delivery of medication counseling, education level achieved, and patient perceptions
regarding benefits and detriments of pharmacy care services. An additional limitation was the breaking
of matches after the matching procedure had been completed that caused minor inequalities between the
size of hospitalized and non-hospitalized patient populations in both study drug cohorts. This resulted
from exclusion of patients that did not have a prescription claim during the follow up period. This
procedure was necessary to prevent misclassification of patients no longer filling prescriptions with the
insurer as non-persistent, but it may have further contributed to the unequal distribution of confounders
between groups.
The primary outcome of interest, persistence, is a surrogate marker for adverse health
outcomes that are expected to follow the inappropriate discontinuation of evidence based therapies for
chronic disease. A comparison of readmission and/or mortality rates between persistent and nonpersistent patients would be useful to fully characterize the adverse effects of medication disruption by
inpatient hospitalization. Moreover, the potential for misclassification surrounding the primary outcome
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must be considered. Although the medication classes selected for this study are recommended for use in
broad populations of patients with diabetes,39 it is possible that the medications were intentionally
stopped by prescribers for legitimate reasons. Such causes may have included intolerable adverse
effects, newly developed contraindications to therapy, or lifestyle control of the medical condition that
precluded the necessity for continued drug treatment. Detection of prescription fills for persistence
confirmation was also limited to claims submitted to the commercial insurer. Prescriptions that were
bought without insurance or with alternative insurance coverage would not be detected and patients
would be at risk for misclassification. We sought to mitigate such bias through the exclusion of patients
that did not have a prescription claim for any medication during the follow up period. Our exclusion of
such patients contributed to an underestimation of persistence if it is presumed that these patients filled
their prescription without reimbursement from Blue Cross Blue Shield of Rhode Island. With claims
data, adherence to prescription medications is determined using the surrogate marker of a prescription
dispensing. It is possible that patients picked up medication but then did not proceed to take it, resulting
in misclassification of baseline adherence or follow up persistence.
Our study is believed to be the first to evaluate persistence patterns following hospitalization in
a commercially insured population with diabetes that was adherent to evidence based therapy prior to
hospitalization. The use of a matched comparator group of patients with diabetes that were not
hospitalized sought to preclude the introduction of bias and improved the interpretability of our results.
The capacity for generalization of our results is limited to a commercially insured population with
diabetes using ACE inhibitors/ARBS or LLDs. Further research evaluating persistence and successive
clinical outcomes in this population is required to better characterize the impact of regimen disruption
secondary to hospitalization. Confirmation of our results is also warranted in nationally representative
populations of elderly and commercially insured patients with diabetes. Future studies using outpatient
claims data would be improved through an integrated analysis with inpatient and outpatient medical
records, which would increase the specificity for identifying true non-persistence. Intentional
medication discontinuation would be detectable in the medical chart, comorbid disease burden would be
verifiable, and information on additional potential confounders would be available for assessment.
Ideally, medical records and claims data will be used together to evaluate the effect of a care transition
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intervention, such as medication reconciliation, in a randomized prospective study conducted across
multiple institutions. Such a large scale and rigorous study methodology is necessary to generate widely
applicable evidence of improved clinical outcomes and to justify funding and implementation of
specific care transition interventions.
In conclusion, hospitalization was found to be a significant risk factor for ACE inhibitor/ARB
discontinuation in commercially insured patients with diabetes without comorbid cardiovascular
disease. Hospitalized patients with cardiovascular disease were more likely to persist with ACE
inhibitor/ARB therapy than non-hospitalized patients with cardiovascular disease. Hospitalization was
not found to disrupt continuation of LLD treatment after discharge, as persistence rates were similar to
non-hospitalized patients. A prescription supply of greater than the number of days in the follow up
period was identified as a strong confounder of persistence with both drug classes. Prescription supply
duration should be considered in future studies measuring persistence. Further evaluation of the
disruptive impact of hospitalization on appropriate medication use in patients with diabetes should
focus on quantifying increased risk of adverse health outcomes with non-persistence and the
effectiveness of care transition interventions on preventing unintentional medication discontinuation.
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APPENDIX A

ICD-9 CODES TO IDENTIFY DIABETES
25000
25032
25070
36202

25001
25033
25071
36203

25002
25040
25072
36204

25003
25041
25073
36205

25010
25042
25080
36206

25011
25043
25081
36207

25012
25050
25082
36641

25013
25051
25083
64801
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25020
25052
25090
64802

25021
25053
25091
64803

25022 25023 25030 25031
25060 25061 25062 25063
25092 25093 3572 36201
64804

APPENDIX B

HEDIS 2009 CPT CODES TO IDENTIFY VISIT TYPE
Nonacute Inpatient CPT Codes
99301 99302 99303 99304 99305 99306 99307 99308 99309 99310 99311 99312 99313 99315
99316 99318 99321 99322 99323 99324 99325 99326 99327 99328 99331 99332 99333 99334
99335 99336 99337
Acute Inpatient CPT Codes
99221 99222 99223 99231 99232 99233 99238 99239 99251 99252 99253 99254
99262 99263 99291
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99255 99261

APPENDIX C

MEDICATIONS WITHIN EACH STUDY MEDICATION CLASS
Ace Inhibitors and Angiotensin Receptor
Blockers (ARB)
Aliskiren
Aliskiren/Hydrochlorothiazide
Benazepril Hydrochloride
Benazepril Hydrochloride/Hydrochlorothiazide
Candesartan Cilexetil
Candesartan Cilexetil/Hydrochlorothiazide Captopril
Captopril/Hydrochlorothiazide
Enalapril Maleate
Enalapril Maleate/Hydrochlorothiazide
Eprosartan Mesylate
Fosinopril Sodium
Fosinopril Sodium/Hydrochlorothiazide
Hydrochlorothiazide/Irbesartan
Hydrochlorothiazide/Lisinopril
Hydrochlorothiazide/Moexipril Hydrochloride
Hydrochlorothiazide/Losartan Potassium
Hydrochlorothiazide/Olmesartan Medoxomil
Hydrochlorothiazide/Quinapril Hydrochloride
Hydrochlorothiazide/Telmisartan
Hydrochlorothiazide/Valsartan
Irbesartan
Lisinopril
Losartan Potassium
Losartan Potassium
Moexipril Hydrochloride
Olmesartan Medoxomil
Perindopril Erbumine
Quinapril Hydrochloride
Ramipril
Telmisartan
Trandolapril
Trandolapril/Verapamil
Valsartan
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Lipid Lowering Drugs (LLD)
Atorvastatin Calcium
Amlodipine Besylate/Atorvastatin Calcium
Cholestyramine
Colesevelam Hydrochloride
Colestipol Hydrochloride
Colestipol Hydrochloride, Micronized
Ezetimibe
Ezetimibe/Simvastatin
Fenofibrate
Fenofibrate, Micronized
Fenofibric Acid
Fluvastatin Sodium
Gemfibrozil
Lovastatin
Lovastatin/Niacin
Niacin
Niacin/Simvastatin
Omega-3-Acid Ethyl Esters
Pravastatin Sodium
Rosuvastatin Calcium
Simvastatin

APPENDIX D

COMORBIDITY SCORE DISTRIBUTION BY MEDICATION CLASS
(Patients that were eligible for matching and were matched)
Comorbidity Score

ACE/ARB
(N=207 each group)a
% (N)

0
55.56 (115)
1
15.94 (33)
2
15.46 (32)
3
6.28 (13)
4
2.90 (6)
5
0.48 (1)
6
0.97 (2)
7
0.97 (2)
8
0.97 (2)
9
0 (0)
10
0.48 (1)
a
207 hospitalized and non-hospitalized patients each (total 414)
b
206 hospitalized and non-hospitalized patients each (total 412)
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LLD
(N=206 each group)b
% (N)
53.40 (110)
11.65 (24)
16.99 (35)
8.74 (18)
3.40 (7)
0.49 (1)
1.94 (4)
1.46 (3)
0.49 (1)
0.97 (2)
0.49 (1)

APPENDIX E

CONFOUNDER ASSESSMENT
ACE Inhibitor/ARB Cohort

Multivariable Logistic
Regression Model

Parameter Estimate
(β)

P-value

Full Modela

-0.931

0.028

Full Model - Age

-0.911

0.030

Full Model - Gender

0.931

0.028

Full Model - Comorbidity Score
Group

-0.929

0.028

Full Model - Respiratory
Disease

-0.915

0.031

Full Model - Mental Health
Disease

-0.936

0.027

Full Model - Days' Supply

-0.662

0.092

Full Model - Regimen
Complexity

-0.811

0.047

Full Model - Diabetes Severity

-1.011

0.016

a

The full model was the standard for comparison and consisted of all potential confounders and the
two-way interaction between hospitalization and cardiovascular disease
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APPENDIX E

CONFOUNDER ASSESSMENT
Lipid Lowering Drugs

Multivariable Logistic
Regression Model

Parameter Estimate
(β)

P-value

Full Modela

-0.040

0.914

Full Model - Age

-0.037

0.920

Full Model - Gender

-0.040

0.914

Full Model - Comorbidity Score
Group

-0.122

0.735

Full Model - Cardiovascular
Disease

-0.040

0.913

Full Model - Respiratory
Disease

-0.074

0.839

Full Model - Mental Health
Disease

-0.036

0.922

Full Model - Days' Supply

0.197

0.572

Full Model - Regimen
Complexity

-0.181

0.607

Full Model - Diabetes Severity

-0.107

0.765

a

The full model was the standard for comparison and consisted of all potential confounders
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APPENDIX F

Calibration Assessment of the Final Multivariable Logistic Regression Model

Model

Hosmer and Lemeshow
Goodness of Fit

C Statistic

Final ACE inhibitor/ARB Modela

0.23

0.77

Final LLD Modelb

0.87

0.73

a

The final model consisted of all potential confounders and the two-way interaction between hospitalization
and cardiovascular disease
b
The final model consisted of all potential confounders
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